How to Get Wegovy Without Insurance: Your Options

Wegovy carries a list price of roughly $1,300 to $1,400 per month, and without insurance picking up even part of that tab, paying out of pocket can feel impossible. The good news is that several legitimate paths exist for lowering the cost or finding alternatives, from the manufacturer’s own assistance programs to compounded versions and older, far cheaper weight-loss medications. Each option comes with trade-offs in cost, effectiveness, and safety, and understanding those trade-offs is the difference between saving money wisely and taking a real risk with your health.

What Wegovy Costs Without Insurance

At most retail pharmacies, Wegovy’s cash price sits in the $1,300 to $1,400 range for a month’s supply at any maintenance dose. That number reflects the wholesale acquisition cost set by Novo Nordisk, plus whatever markup the pharmacy adds. For perspective, even a year of treatment at the lowest end of that range comes to more than $15,000. The annual cost of obesity-related medical care in the United States was estimated at nearly $173 billion in 2019, a figure that has roughly doubled over the past couple of decades, yet most of that spending goes toward treating complications rather than covering the medications that could prevent them.¹ The mismatch between how much obesity costs the healthcare system and how little coverage exists for the drugs that treat it is the core frustration driving people to look for workarounds.

If you have no insurance at all, or your plan specifically excludes weight-loss medications (which many do), you are looking at paying the full sticker price unless you pursue one of the options below. Even some insured patients discover their plan covers Wegovy for type 2 diabetes management but not for weight loss, or requires a prior authorization that can take weeks and still end in denial. The practical result is the same: you need a cheaper path.

Manufacturer Savings and Assistance Programs

Novo Nordisk runs two programs worth knowing about. The first is a savings card, sometimes called a copay card, designed for people who do have commercial insurance but face a high copay. If your plan covers Wegovy but your out-of-pocket share is steep, the savings card can reduce your monthly cost to as little as $0 to $25 for up to a set number of fills. The catch is that this card is generally available only to commercially insured patients. If you are on Medicare, Medicaid, or a government-funded plan, you typically do not qualify.

The second program is Novo Nordisk’s Patient Assistance Program (PAP), which provides Wegovy at no cost to eligible patients who are uninsured or underinsured and meet income requirements. You generally need to demonstrate that your household income falls below a certain threshold, and your prescribing clinician has to participate in the application process. The paperwork is not trivial, and approval can take several weeks, but for people who qualify, this is the single most direct route to getting brand-name Wegovy without paying for it. Details and eligibility criteria are available on Novo Nordisk’s patient assistance website and can change from year to year, so check the current requirements before assuming you qualify or don’t.

Compounded Semaglutide

During the period when semaglutide was on the FDA’s drug shortage list, compounding pharmacies were legally permitted to produce their own versions. These compounded products became enormously popular, often costing a fraction of Wegovy’s retail price. In early 2025, the FDA declared the semaglutide shortage resolved, which significantly narrows the legal window for compounders to continue making and selling the drug. Some compounding pharmacies have challenged that determination in court, and the regulatory landscape is still shifting, so availability depends partly on where you live and when you are reading this.

If you can still access compounded semaglutide, the price advantage is real. Monthly costs through telehealth-affiliated compounding pharmacies have typically ranged from roughly $150 to $500, depending on dose, pharmacy, and whether you are bundling in consultation fees. But the savings come with meaningful caveats. The American Diabetes Association issued a formal statement noting that compounded GLP-1 receptor agonist products are not identical to the FDA-approved versions.² One specific concern involves the use of salt forms of semaglutide, such as semaglutide sodium or semaglutide acetate, as a substitute for the semaglutide base used in Wegovy. These salt forms are not chemically identical to the original molecule, which could lead to clinically meaningful differences in both effectiveness and safety.²

That does not mean every compounded product is dangerous, but it does mean you are not getting a generic version of Wegovy. You are getting a pharmacy’s in-house formulation that has not gone through the same clinical trials, purity testing, or manufacturing oversight. If you go this route, choosing a pharmacy that operates under FDA-registered 503B outsourcing facility rules (which are subject to more regulatory scrutiny than standard 503A compounding pharmacies) offers somewhat more assurance, though it is not equivalent to buying an FDA-approved product.

Lower-Cost Alternative Weight-Loss Medications

Semaglutide is not the only medication that produces meaningful weight loss. Several older drugs are available as generics and cost dramatically less. Research estimating the minimum manufacturing costs for anti-obesity medications found that some oral treatments could be produced at remarkably low prices: roughly $7 per course for orlistat and about $5 for a phentermine/topiramate combination, while naltrexone/bupropion was pricier at around $54.³ Even at actual retail prices, which are higher than those manufacturing-floor estimates, these medications are a world away from Wegovy’s four-figure monthly bill. A month’s supply of generic phentermine/topiramate, for instance, typically runs a few hundred dollars at most without insurance, and often well under $100 with a pharmacy discount card.

The trade-off is effectiveness. These older medications produce less weight loss on average than semaglutide. One analysis comparing a phentermine/topiramate maintenance program against tirzepatide (a newer GLP-1/GIP dual agonist) found that phentermine/topiramate achieved about 9.8% weight loss from baseline compared with roughly 20.9% for tirzepatide, at a net monthly cost of around $300 versus $530.⁴ So you get less weight loss, but at a meaningfully lower price. For someone who cannot afford Wegovy at all, a medication that produces 10% body weight loss is still a significant clinical benefit. It is enough to improve blood pressure, blood sugar, joint pain, and sleep apnea in many people.

Here are the main alternatives and what to expect from each:

Phentermine/topiramate: The most effective of the older oral options, combining an appetite suppressant with a drug originally used for seizures and migraines. Available as a generic. Typical weight loss is in the range of 7 to 10% of body weight.
Naltrexone/bupropion: Combines an opioid antagonist with an antidepressant. Targets cravings and the reward pathways involved in overeating. Generic versions are available. Weight loss tends to be more modest, in the range of 5 to 8%.
Orlistat: Works by blocking fat absorption in the gut rather than suppressing appetite. Available over the counter at a lower dose (Alli) and by prescription at a higher dose (Xenical). Effective but comes with well-known gastrointestinal side effects if you eat high-fat meals.
Phentermine alone: One of the cheapest options. Approved for short-term use, though some clinicians prescribe it for longer periods off-label. It is a stimulant and carries restrictions for people with heart conditions or uncontrolled blood pressure.

None of these will replicate the 15 to 17% average body weight loss seen in the Wegovy clinical trials. But they are accessible, affordable, and backed by evidence. For many people whose primary barrier is cost, they are a far better option than no treatment at all.

Using a GLP-1 to Lose, Then Switching to Maintain

One strategy gaining traction is using a GLP-1 receptor agonist for the initial weight-loss phase, then transitioning to a cheaper medication once you reach your goal. A real-world study found that patients who had been successfully treated with GLP-1 receptor agonists could maintain their weight loss after switching to generic, older-generation anti-obesity medications.⁵ The implication is practical: you might not need to stay on Wegovy forever to keep the weight off, as long as you have a plan for what comes next.

This approach has appeal for people who can afford Wegovy for a limited time, perhaps through a short-term savings program, a temporary employer benefit, or by dipping into savings for six to twelve months. The idea is to use the most effective tool during the active weight-loss phase, when you are changing eating patterns and building new habits, and then step down to a cheaper maintenance medication that keeps the metabolic signals pointed in the right direction. One modeling analysis estimated that such an alternative weight-maintenance program using phentermine/topiramate could generate lifetime savings of about $29,800 per person compared with staying on a newer agent indefinitely.⁴

The strategy is not without risk. Weight regain after stopping GLP-1 receptor agonists is well documented, and the degree of regain varies. Some people maintain most of their loss on an alternative medication, while others regain substantially. The success likely depends on factors like how much behavioral change happened during the GLP-1 phase, which maintenance medication is used, and individual biology. If you are considering this path, it is worth having an explicit conversation with your clinician about the transition plan before you start rather than figuring it out when the prescription runs out.

Pharmacy Discount Programs and Cash-Pay Strategies

If you are paying cash for brand-name Wegovy, pharmacy discount platforms like GoodRx, RxSaver, and similar tools can sometimes shave a few hundred dollars off the retail price, though the savings on a drug this expensive tend to be modest in percentage terms. You might see offers bringing the cost from $1,400 down to $1,100 or $1,200, which helps but does not solve the underlying affordability problem. These platforms work better for the generic alternatives mentioned above, where the starting price is already much lower and a 30 to 50% discount can make the medication genuinely affordable.

Some independent and compounding pharmacies offer cash-pay pricing that undercuts the large chains. It is worth calling around, especially to pharmacies that specialize in weight management or endocrinology patients. Mail-order pharmacies sometimes offer lower prices as well, particularly those affiliated with telehealth platforms that prescribe weight-loss medications. Just be cautious about any pharmacy you have never heard of offering prices that seem too good to be true, especially online. Counterfeit injectable medications are a real and growing problem, and the consequences of injecting a contaminated or mislabeled product are serious.

What to Know About Telehealth Prescribers

A large number of telehealth companies now offer weight-loss consultations and can prescribe Wegovy or its alternatives. Some of these platforms bundle the prescription, the medication (often compounded semaglutide), and ongoing check-ins into a single monthly fee. Prices vary widely, from under $200 per month to over $500, depending on the medication, the dose, and what level of clinical support is included.

The quality of these services ranges just as widely. At the better end, you get a licensed clinician who reviews your medical history, checks for contraindications, titrates your dose appropriately, and follows up on side effects. At the worse end, you get a questionnaire, a rubber-stamped prescription, and no meaningful clinical oversight. A few things to look for when evaluating a telehealth prescriber:

Clinician credentials: Is your prescriber a physician, nurse practitioner, or physician assistant licensed in your state? Can you verify their license?
Dose titration: Semaglutide should be started at a low dose and gradually increased. Any service that starts you at a high dose without titration is cutting corners in a way that increases your risk of severe nausea and other side effects.
Pharmacy sourcing: Where does the medication come from? A 503B outsourcing facility has more oversight than a 503A compounding pharmacy. A service that won’t tell you where the medication is compounded is a red flag.
Ongoing monitoring: Does the platform require follow-up appointments? Do they check in about side effects? Weight-loss medication management is not a one-and-done prescription.

Telehealth can be a perfectly reasonable way to access treatment, especially if you live in an area with few obesity medicine specialists. Just treat the evaluation process with the same scrutiny you would apply to any medical provider.

Risks of Unregulated and Foreign Sources

When a drug costs over $1,000 a month and demand outpaces supply, a gray market inevitably appears. You can find injectable semaglutide sold through social media, overseas online pharmacies, and informal networks. The prices are often dramatically lower, sometimes a few hundred dollars for what is claimed to be a multi-month supply. The risks are equally dramatic.

Products obtained outside regulated channels may contain the wrong active ingredient, the wrong concentration, or contaminants introduced during unregulated manufacturing. Injectable medications carry special risks because they bypass the body’s natural barriers against infection and toxins. A pill made with questionable ingredients might cause a stomachache; a contaminated injection can cause an abscess, a systemic infection, or worse. The FDA has issued warnings about adverse events linked to products sold as semaglutide that turned out to contain different substances entirely.

Buying from a foreign pharmacy, even one that appears legitimate, introduces additional uncertainty. Drug regulation varies enormously from country to country, and a product that looks identical to Wegovy in its packaging may have been manufactured under completely different quality standards. There is also the legal dimension: importing prescription medications into the United States for personal use occupies a legal gray area that customs enforcement may or may not act on, and you have little recourse if something goes wrong with a product you purchased from another country.

Older Medications as a Bridge, Not a Consolation Prize

There is a tendency, understandable given the hype around GLP-1 receptor agonists, to view the older weight-loss medications as second-rate options you settle for when you cannot get the “real” treatment. That framing sells them short. The medications that existed before semaglutide were approved precisely because they work. Phentermine/topiramate, in particular, produces clinically significant weight loss, improves metabolic markers, and has a long track record. It is also one of the most affordable options available, with estimated manufacturing costs as low as $5 per course.³

The clinical question is not whether these medications work. It is whether they work well enough for your specific situation. If you need to lose 30% of your body weight to resolve severe metabolic disease, a medication that typically delivers 8 to 10% loss may not be sufficient on its own. But if your goal is a more modest 10 to 15% reduction, or if you are using the medication alongside meaningful dietary and exercise changes, an older generic can get you there at a price that does not require a second mortgage. And as the maintenance data suggest, even patients who achieve large initial losses on a GLP-1 agonist may be able to sustain much of that progress on a cheaper drug afterward.⁵

When the Math Changes

The landscape around Wegovy pricing is not static. Novo Nordisk has faced mounting political and public pressure over the drug’s price, and several developments could shift the calculus in the coming years. Generic semaglutide for weight loss does not yet exist in the United States, but patent expirations and legal challenges could eventually open the door. Meanwhile, competing GLP-1 and dual-agonist drugs from other manufacturers are entering the market, and competition tends to push prices down over time, though how quickly remains uncertain.

Medicare coverage is another factor worth watching. Historically, Medicare has been barred from covering weight-loss medications, but legislative proposals to change that restriction have gained bipartisan support. If Medicare begins covering anti-obesity drugs, it would not only help enrollees directly but would also put downward pressure on pricing across the board, since Medicare’s purchasing power is enormous. Some state Medicaid programs have also started covering GLP-1 agonists for weight loss, though coverage varies widely by state and can change with each budget cycle.

For anyone making a decision right now, the practical takeaway is that the current price is likely the highest Wegovy will ever be. That does not mean you should wait indefinitely, since the health costs of untreated obesity accumulate in the meantime. But it does mean the options you choose today, whether that is a manufacturer assistance program, a compounded version, or a cheaper alternative medication, are likely bridging strategies. The market is moving, even if it is not moving fast enough for people who need affordable treatment today.